Scale-up Cealus Health starts key study on microbiome product

June 28, 2021

Amsterdam UMC scale-up company Caelus Health has reached an important milestone.

Caelus Health recently started a key clinical trial in individuals suffering from Metabolic Syndrome or pre-diabetes; these individuals are at risk of developing Type 2 diabetes.

The microbiome product based on a single micro-organism (named A. soehngenii) may delay or even prevent the onset of diabetes. The trial is a final step in the development and registration of this product as a food supplement following successful completion of the previous study.

Caelus Health was established in close cooperation with Wageningen University.

Read more here